

Supplementary Figure 9. TM4SF1 is negatively correlated with immunotherapy efficacy. (A) Statistical analysis of CD8+ T cell counts and proportion of GZMB+ or PD-1+ cells among CD8+ T cells in HTVi-induced HCC model with different treatments (n=5). (B) Preoperative, postoperative, and post- anti-PD-1 treatment MRI or CT images of the rest of patients in prospective cohort 2. (C) Statistical analysis of CD8+ T cell counts in patients' tumor slides (n=10). (D) Ki-67 index of patients who received immunotherapy, based on pathological reports (n=7). (E) TM4SF1 mRNA expression in dataset ERP117672. Data are represented as the means±standard deviation. *P*-values for (A), (C) and (D) were calculated using the unpaired Student's *t*-test. *P*-values for (E) were calculated using unpaired Mann-Whitney test. **P*<0.05, ***P*<0.01, ****P*<0.001, *****P*<0.0001. TM4SF1, transmembrane 4 L six family member 1; GZMB, granzyme B; PD-1, programmed death 1; HTVi, hydrodynamic tail vein injection; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; CT, computed tomography.

 https://doi.org/10.3350/cmh.2024.0934